MNPR - Income Statement - Monopar Therapeutics Inc.

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015
REVENUE
Revenue	0	0	0	0	0	0	0	0	0	0
GROSS PROFIT
Cost Of Revenue	0	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0	0
OPERATING INCOME
Operating Expenses	16.2	8.8	10.5	9.1	6.5	4.3	3.4	16.6	1.2	0.7
Selling, General and Administrative Expenses	3 155.7	3.2	2.9	2.6	2.4	2.4	1.6	1.2	0.9	0.6
Research and Development Expenses	13 006.0	5.6	7.6	6.5	4.1	2.0	1.8	15.4	0.3	0.1
Operating Income	(16 161.7)	(8.8)	(10.5)	(9.1)	(6.5)	(4.3)	(3.4)	(16.6)	(1.2)	(0.7)
PRE-TAX INCOME
Interest Income Expense	0	0	0	0	0	0	0.1	48.3 K	7.23 K	0
Total Other Income	575.3	0.4	21.2 K	24 K	0.2	98.9 K	31.1 K	48.3 K	8.03 K	1.25 K
Pre-Tax Income	(15 586.4)	(8.4)	(10.5)	(9.1)	(6.3)	(4.2)	(3.3)	(16.6)	(1.2)	(0.7)
NET INCOME
Tax Provision	0	0	21.2 K	24 K	81.9 K	98.9 K	71.6 K	(2.1)	800	(0.7)
Net Income	(15 586.4)	(8.4)	(10.5)	(9.1)	(6.2)	(4.1)	(3.2)	(16.6)	(1.2)	(0.7)
EPS	411	0.58	0.83	0.73	0.57	0.39	0.31	1.59	0.11	0.0649

Free